Immunotherapies: Exploiting the Immune System for Cancer Treatment

被引：104

作者：

Koury, Jeffrey ^{[1
]}

Lucero, Mariana ^{[1
]}

Cato, Caleb ^{[1
]}

Chang, Lawrence ^{[1
]}

Geiger, Joseph ^{[1
]}

Henry, Denise ^{[1
]}

Hernandez, Jennifer ^{[1
]}

Hung, Fion ^{[1
]}

Kaur, Preet ^{[1
]}

Teskey, Garrett ^{[1
]}

Tran, Andrew ^{[1
]}

机构：

[1] Western Univ Hlth Sci, Grad Coll Biomed Sci, Pomona, CA 91766 USA

来源：

JOURNAL OF IMMUNOLOGY RESEARCH | 2018年 / 2018卷

关键词：

TUMOR-INFILTRATING LYMPHOCYTES; T-CELL-ACTIVATION; HEPATOCYTE GROWTH-FACTOR; RECOMBINANT INTERLEUKIN-2 THERAPY; METASTATIC MELANOMA PATIENTS; PURIFIED HUMAN INTERLEUKIN-2; ANTIBODY FUSION MOLECULES; TERM-FOLLOW-UP; BISPECIFIC ANTIBODIES; C-MET;

D O I：

10.1155/2018/9585614

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Cancer is a condition that has plagued humanity for thousands of years, with the first depictions dating back to ancient Egyptian times. However, not until recent decades have biological therapeutics been developed and refined enough to safely and effectively combat cancer. Three unique immunotherapies have gained traction in recent decades: adoptive T cell transfer, checkpoint inhibitors, and bivalent antibodies. Each has led to clinically approved therapies, as well as to therapies in preclinical and ongoing clinical trials. In this review, we outline the method by which these 3 immunotherapies function as well as any major immunotherapeutic drugs developed for treating a variety of cancers.

引用

页数：16

共 131 条

[1] Bispecific Antibodies (bsAbs): Promising Immunotherapeutic Agents for Cancer Therapy
Acheampong, Desmond O.
Adokoh, Christian K.
Ampomah, Paulina
Agyirifo, Daniel S.
Dadzie, Isaac
Ackah, Francis A.
Asiamah, Ernest A.
[J]. PROTEIN AND PEPTIDE LETTERS, 2017, 24 (05) : 456 - 465
[2] A mini-review of c-Met as a potential therapeutic target in melanoma
Al-U'datt, Doa'a G. F.
Al-Husein, Belal A. A.
Qasaimeh, Ghazi Raji
[J]. BIOMEDICINE & PHARMACOTHERAPY, 2017, 88 : 194 - 202
[3] [Anonymous], 2017, CANC DISCOVOVERY
[4] PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Ansell, Stephen M.
Lesokhin, Alexander M.
Borrello, Ivan
Halwani, Ahmad
Scott, Emma C.
Gutierrez, Martin
Schuster, Stephen J.
Millenson, Michael M.
Cattry, Deepika
Freeman, Gordon J.
Rodig, Scott J.
Chapuy, Bjoern
Ligon, Azra H.
Zhu, Lili
Grosso, Joseph F.
Kim, Su Young
Timmerman, John M.
Shipp, Margaret A.
Armand, Philippe
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (04) : 311 - 319
[5] 2015: The Year of Anti-PD-1/PD-L1s Against Melanoma and Beyond
Ascierto, Paolo A.
Marincola, Francesco M.
[J]. EBIOMEDICINE, 2015, 2 (02): : 92 - +
[6] High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993
Atkins, MB
Lotze, MT
Dutcher, JP
Fisher, RI
Weiss, G
Margolin, K
Abrams, J
Sznol, M
Parkinson, D
Hawkins, M
Paradise, C
Kunkel, L
Rosenberg, SA
[J]. JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (07) : 2105 - 2116
[7] Bispecific T-Cell Engaging Antibodies for Cancer Therapy
Baeuerle, Patrick A.
Reinhardt, Carsten
[J]. CANCER RESEARCH, 2009, 69 (12) : 4941 - 4944
[8] The role of HGF/c-MET signaling pathway in lymphoma
Bao Quoc Lam
Dai, Lu
Qin, Zhiqiang
[J]. JOURNAL OF HEMATOLOGY & ONCOLOGY, 2016, 9 : 1 - 8
[9] BERENDT MJ, 1980, J EXP MED, V151, P69, DOI 10.1084/jem.151.1.69
[10] Adoptive Transfer of Tumor-Infiltrating Lymphocytes in Patients with Metastatic Melanoma: Intent-to-Treat Analysis and Efficacy after Failure to Prior Immunotherapies
Besser, Michal J.
Shapira-Frommer, Ronnie
Itzhaki, Orit
Treves, Avraham J.
Zippel, Douglas B.
Levy, Daphna
Kubi, Adva
Shoshani, Noa
Zikich, Dragoslav
Ohayon, Yaara
Ohayon, Daniel
Shalmon, Bruria
Markel, Gal
Yerushalmi, Ronit
Apter, Sara
Ben-Nun, Alon
Ben-Ami, Eytan
Shimoni, Avichai
Nagler, Arnon
Schachter, Jacob
[J]. CLINICAL CANCER RESEARCH, 2013, 19 (17) : 4792 - 4800

← 1 2 3 4 5 6 7 8 9 10 →